Can anyone tell me how to interpret the chairman of the thoracic society of Australia and NZ joining RSH (another respiratory monitoring company in the space) as a director instead of RAP - isn’t RAP so much more advanced with respiratory monitoring?? RAP has a market cap over double RSH so I would imagine they are?
Thoughts and analysis please?